Vol.48, No.2, Oct. 2020
Medical Innovation and Longevity (the 2nd session): “Centenarian heart” and “cancer genome medicine”
 
Contents
 
●EditorialKurihara M306Full text
 
●Round table discussion
　Medical Innovation and Longevity (the 2nd session): “Centenarian heart” and “cancer genome medicine”
　　　　　　　　　　Organized by Kurihara C，Cooperated by Fukunaga A, Nakayama R, Saio T
307-53
Abstract
Fig.1～7
　Part 1 History and future of artificial heart development and cardiac physiologySakamoto T，Ishii T，Takaku F，
Atsumi E，Kurihara M		309-33
　Part 2 Cancer genome medicine and information technology: ChrovisNishimura K，Participants of the Part 1334-50
　Additional comments on COVID-19Participants of the Part 1351-3
 
●Articles
　Original article：Utilization of Information and Communication Technology in IRBs
　　as a countermeasure against the COVID-19 outbreak and future challenges		Tsutsumi N，Kurihara C，
Matsuyama K，et al．		 355-66Full text
　Progress and Challenges of CTDS:
　　From the perspective of the pharmaceutical industry		Kato T，Aoki S，Ohtsuka W，et al． 367-74Abstract
　Use of the National Cancer Registry Data in JapanShibata A 375-82Abstract
　A review on pain of decubitus injuries: Focusing on clinical practice guidelinesSaio T 383-90Abstract
 
●Explanatory articles and translations
　On the Japanese translation of the report by UAEM and TranspariMED
　　on clinical trial result registration: Global concern and challenges in Japan		Kurihara C，Saio T 391-8Full text
　Clinical trial transparency at US universities
　　Compliance with U.S. law and global best practices		UAEM，TranspariMED
（Trans. by Saio T，Kurihara C）		 399-409Full text
 
　Outline of the FDA guidance on adaptive designs for clinical trials:
　　With an overview of adaptive designs		Saio T，Kurihara C 411-6Abstract
　Adaptive Designs for Clinical Trials of Drugs and Biologics
　　Guidance for Industry		U.S. Department of Health and Human Services
Food and Drug Administration，
Center for Drug Evaluation and Research (CDER);
Center for Biologics Evaluation and Research (CBER)
（Trans. by Saio T，Kurihara C）		 417-48
 
●Instructions for authors［Japanese］＆［English］ 449-57Full text
 
●Editor’s noteSaio T459Full text


Back to Rinsho Hyoka(Clinical Evaluation) home page
Back to Contents